Genflow trial hits endpoint; 80 Mile agrees takeover

Insilico Medicine has launched its Virtual Aging Cell webpage and previewed a multi-agent driven platform that uses biological age as a core condition for simulating cellular dynamics. The platform deploys agent swarms across six biological scales—molecular, intracellular, intercellular, tissue, organ, and organism—to model differentiation, reprogramming, and aging, aiming to support target identification and drug discovery. The launch follows a decade of work including the PreciousGPT model series, with the company noting it has nominated 33 preclinical candidates since 2021, 13 of which have received IND approvals or clearances. Insilico will present further details at the ARDD 2026 conference in Boston.

3696.HK ▲

PR Newswire·36dRead more →

Life Biosciences appoints Stephen Webster to board of directors

Life Biosciences has appointed Stephen Webster to its board of directors, effective August 1, 2026. Webster is a biotechnology executive who has served as chief financial officer of three public companies and played a key role in multiple financings, commercial launches, and acquisitions. He previously led approximately $1 billion in equity financings at Spark Therapeutics, oversaw its 2015 initial public offering, supported the commercial launch of LUXTURNA, and helped lead the company's $4.3 billion acquisition by Roche. Life Biosciences is a clinical-stage biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, with a lead program in development for optic neuropathies.

ROP.SW

Longevity & Life Extension

GlobeNewswire·40dRead more →

▲

Ollin, Beeline, New Limit raise large rounds amid cautious biotech market

Several biotechs have landed sizable funding rounds even as investors remain selective. Ollin Biosciences announced a $330 million series B round co-led by TCGX and Arch Venture Partners to advance its next-generation VEGF/Ang2 bispecific antibody OLN324 for diabetic macular edema and wet age-related macular degeneration. Beeline Medicines, a Bristol Myers Squibb spinout backed by Bain Capital, emerged from stealth with $300 million to develop five in-licensed immunology drugs, including the phase 2 lupus pill afimetoran. New Limit closed a $435 million series C round backed by Founders Fund and Lilly Ventures, reaching an estimated $3.1 billion valuation, and plans to begin clinical trials next year for its epigenetic reprogramming therapy targeting liver aging.

Longevity & Life Extension ▲Biotech & Genomic Medicine

PharmaVoice·81dRead more →